Group 1 - The core viewpoint is that the Hong Kong stock market's innovative drug concept stocks continue to show strong momentum, particularly with CSPC Pharmaceutical Group (01093), which reached a peak price of HKD 11.5 and is currently trading at HKD 11.23, reflecting a 4.47% increase [1] - Technical analysis indicates that CSPC's stock price has broken through several key technical levels, forming a bullish pattern, although technical indicators show signs of overheating, suggesting investors should remain cautious [1] - The current support levels for CSPC are at HKD 10.2 (Support 1) and HKD 9.7 (Support 2), while resistance levels are at HKD 11.9 (Resistance 1) and HKD 12.6 (Resistance 2) [1] Group 2 - Haitong International's research report assigns a PE ratio of 29.1x for CSPC for the fiscal year 2026, up from 18.2x, with a target price of HKD 13.11 based on a forecasted EPS of HKD 0.45 [3] - Recent performance of CSPC's related derivatives has been outstanding, with products like the Societe Generale bull certificate (65724) and HSBC bull certificate (65641) recording increases of 110% and 112% respectively, compared to a 16.42% rise in the underlying stock [3] - For investors optimistic about the market, options such as the call warrants with exercise prices around HKD 12.98 and HKD 12.99, offering leverage of 4.4x and 4.2x respectively, are recommended [6] Group 3 - For bearish investors, options like the JPMorgan bear certificate (54424) with a redemption price of HKD 9.2 and a leverage of 4.5x are suitable, while UBS bear certificate (66328) and HSBC bear certificate (65200) offer higher leverage of 9.6x and 7.2x respectively [9] - CSPC is currently testing the key resistance level of HKD 11.9, raising questions about whether the recent price increase is a technical breakout or a short-term overheating [12]

Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團全球創新放射性產品 SIR-Spheres®釔[ 90Y]微球注射液 提前正式獲得 FDA 批准新增適應症 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 SIR-Spheres®釔[ 90Y]微球注射液，是一款針對肝臟惡性腫瘤的選擇性內放射治療產品， 採用全球領先的介入技術將釔[ 90Y]樹脂微球注入肝臟腫瘤血管，釋放高能量 β 放射線 殺滅腫瘤細胞，兼具了放射性藥物和精准介入治療的雙重優勢。本次新適應症的獲批是 基於一項前瞻性、多中心、開放標籤的臨床試驗（「DOORwaY90」）的中期結果。該 試驗中期數據顯示，DOORwaY90 成功達到預先設定的共同主要終點：經獨立中 ...